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Background: Oral squamous cell carcinoma (OSCC) patients are at high risk of loco-regional recurrence and 5-year
survival rates are about 50%. Identification of patients at high risk of recurrence will enable rigorous personalized
post-treatment management. Most novel biomarkers have failed translation for clinical use because of their limited
successful validation in external patient cohorts. The aim of this study was to determine the prognostic significance
of alterations in sub-cellular expression of S100A2, a pro-tumorigenic calcium binding protein, identified as a
candidate biomarker in our proteomic analysis in OSCC and validation of its clinical utility in an external cohort.
Methods: In a retrospective study, immunohistochemical analysis of S100A2 was carried out in 235 Indian OSCC
(Test set) and 129 normal oral tissues, correlated with clinicopathological parameters and disease outcome over
122 months for OSCC patients following the REMARK criteria. The findings were validated in an external cohort
(Validation set 115 Canadian OSCC and 51 normal tissues) and data analyzed using the R package.
Results: Significant increase in cytoplasmic and decrease in nuclear S100A2 expression was observed in OSCC in
comparison with normal tissues. Cox multivariable regression analysis internally and externally validated cytoplasmic
S100A2 association with tumor recurrence. Kaplan Meier analysis of patients stratified to high and low risk groups
showed significantly different recurrence free survival (Test set- log rank test, p = 0.005, median survival 16 and
69 months respectively and Validation set - p < 0.00001, median survival 9.4 and 59.9 months respectively); 86% and
81% of patients who had recurrence were correctly stratified into the high risk group. Seventy percent and 81%
patients stratified into low risk group did not show cancer recurrence within 1 year in Test and Validation sets.
Conclusions: Our study provided clinical evidence for the potential of cytoplasmic S100A2 overexpression as a
predictor of recurrence risk in OSCC patients. A unique translational aspect of our study is validation of S100A2 as
prognostic marker in two independent cohorts (Canadian and Indian) suggesting this protein is likely to find
widespread utility in clinical practice for identifying oral cancer patients at high risk of disease recurrence.
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Oral squamous cell carcinoma (OSCC) is the tenth most
prevalent cancer accounting for almost 300,000 new
cases annually worldwide [1]. OSCC is the major subtype
of head and neck squamous cell carcinoma (HNSCC) and
accounts for two-thirds of the cases occurring in least
developed countries [2]. OSCCs are often preceded by
development of clinically distinct oral lesions; on an
average about one percent of oral lesions transform into
cancer annually [3,4]. Despite improvements in treatment
strategies the prognosis of these patients remains largely
unsatisfactory, due to loco-regional recurrence. The 5-year
survival rates are about 50%, and the prognosis of
advanced cases has not improved much over the past 4
decades [2]. At present, the most important prognostic
factors include histological tumor grade, stage, depth of
tumor invasion and involvement of regional lymph nodes
at the time of diagnosis. In search of biomarkers of diag-
nostic or prognostic relevance, tissue proteomic analysis
of OSCC using iTRAQ labeling liquid chromatography-
mass spectrometry led to the identification of differential
expression of S100A2 in OSCC in comparison with histo-
logically normal oral mucosa [5,6].
S100A2, an 11.4 kDa protein, is a member of the S100
family of calcium-binding proteins that have diverse
functions regulating a variety of cellular processes such
as differentiation, regeneration, cell growth, and signal
transduction in neoplastic cells [7]. S100A2 is distributed
in the nucleus and cytoplasm of keratinocytes in normal
human epidermis and is a component of the epidermal
differentiation complex. The functional status of S100A2
protein was determined by interaction with other pro-
teins, homodimers with S100 family members or hetero-
dimers with other proteins in particular, with p53 and
p63 [8]. Expression of S100A2 protein was found to be
deregulated in a variety of tumor types. Initially dimin-
ished expression of S100A2 protein was reported in lung
and gastric cancers [9-11]. However, several later studies
have shown overexpression of S100A2 in other cancers
including non-small cell lung cancer, esophageal, ovar-
ian, bladder, breast, thyroid, melanoma and pancreatic
cancer [12-19]. Recent studies reported S100A2 protein
is a molecular driver in TGF-β induced cell invasion and
migration in hepatic carcinoma [20]. Moreover, ectopic
overexpression of S100A2 induces lung metastasis in
mice [21]. Despite these reports, the clinical relevance
of S100A2 expression as a prognostic marker for oral
cancer patients remains to be determined.
We reported overexpression of S100A2 in OSCCs in
proteomic analysis performed using isobaric mass tags
for relative and absolute quantitation (iTRAQ) followed
by multidimensional liquid chromatography/tandem mass
spectrometry [5,6]. We hypothesized that alterations in
S100A2 sub-cellular localization in cytoplasm or nucleuscould influence oral cancer pathogenesis and may correl-
ate with clinical outcome in these patients. In this study,
we determined the clinical significance of alterations in
expression and sub-cellular localization of S100A2 protein
in OSCC by immunohistochemical analysis in an inde-
pendent cohort of patients by comparing its expression to
normal oral epithelium and determining its correlation
with clinico-pathological parameters and disease outcome
over 122 months to investigate its utility as a prognostic
marker for OSCC. The clinical applicability of S100A2 as
a prognostic marker in OSCC was validated in an external
cohort. A unique translational aspect of our findings is the
validation of S100A2 as a prognostic marker in two inde-
pendent cohorts (Canadian and Indian) suggesting this
protein is likely to find widespread utility in clinical prac-
tice for identifying oral cancer patients at high risk of
disease recurrence.
Materials and methods
Study design
This study has been conducted in two institutions, Mount
Sinai Hospital (MSH), Toronto, Canada and All India
Institute of Medical Sciences (AIIMS), New Delhi, India
according to the Reporting Recommendations for Tumor
Marker prognostic Studies (REMARK) guidelines and a
retrospectively written research, pathological evaluation,
and statistical plan [22]. The study design is given in
Figure 1. We have obtained appropriate consent and the
retrospective studies were approved by the relevant re-
search ethics boards prior to commencement.
Patients
Patient demographic, clinical, and pathological data were
recorded in a pre-designed Performa as described previ-
ously [23]. The information documented included clin-
ical TNM staging (tumor, node, metastasis based on the
Union International Center le Cancer TNM classifica-
tion of malignant tumors), site of the lesion, histopatho-
logical grade, age, gender and treatment.
Inclusion criteria: Patients with histopathological
evidence of squamous cell carcinoma of the oral cavity
and a known clinical outcome were inducted into the
study.
Exclusion criteria: Patients diagnosed with squamous
cell carcinoma of the oral cavity but with no available
follow-up data or patients diagnosed with dysplasia con-
comitant with OSCC at the first visit were excluded
from the study.
Test set. Specimen characteristics
Following the above inclusion and exclusion criteria,
archived formalin fixed paraffin embedded (FFPE) tissue
specimens were obtained from 235 OSCC patients
(median age = 49 years; range - 19–85 years) undergoing
Figure 1 Schematic diagram showing the study design.
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Department of Otorhinolaryngology, AIIMS. Wherever
possible histologically normal tissues (n = 88) were taken
from a site at least 5 cm distant from the surgically
resected tumors from OSCC patients. Non-malignant nor-
mal oral tissues (n = 41) were also collected from the
patients attending the Outpatient Department of Dental
Surgery for tooth extraction. Taken together, these 129
oral tissues with histological evidence of normal epithe-
lium constituted the normal group. After excision, tissues
had been immediately snap frozen in liquid nitrogen and
stored at −80°C in the Research Tissue Bank till further
use; one part of the tissue had been collected in 10% for-
malin and embedded in paraffin for histopathological and
immunohistochemical analysis. Histologically confirmedoral normal epithelia and OSCCs as revealed by H&E
staining were used for immunohistochemistry [24]. These
cases comprised the Test set.
Validation set. Specimen characteristics
The patients’ charts with clinico-pathological diagnosis
of OSCC from 2000 to 2010 were retrospectively
reviewed to obtain the clinical information and follow-
up data in the Department of Pathology, MSH. Informa-
tion regarding gender, age, site of lesions at the time of
the initial diagnosis of dysplasia or OSCC was docu-
mented in the clinical database. Following the above
inclusion and exclusion criteria, archived tissue speci-
mens of OSCC patients (n = 115, median age: 62 years;
range: 21–92 years) undergoing curative cancer surgery
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study and 51 paired normal tissues were also obtained
from the archived tissue bank at MSH, Canada.
Treatment
All OSCC patients were treated as per the National
Comprehensive Cancer Network (NCCN) guide lines for
head and neck cancers (www.nccn.org). OSCC patients
with T1 and T2 tumors were treated with radical surgery;
majority of patients with T3 and T4 disease were treated
with radical surgery followed by postoperative radical
radiotherapy [23].
Survival data
After completion of the primary treatment OSCC pa-
tients were followed at regular time intervals in both
Centers AIIMS and MSH for a maximum period of
122 months (mean 23.08 months and median 11.50 months).
Notably, recurrence or death was observed in 51.1%
patients. The medical history, clinical examination, and
radiological evaluation were used to determine whether
the death had resulted from recurrent cancer (relapsing
patients) or from any other causes. Disease-free sur-
vivors were defined as patients free from clinical and
radiological evidence of local, regional, or distant
relapse at the time of the last follow-up. In the current
study, recurrence of the cancer and/or death versus no
recurrence of OSCC was considered to be the clinical
outcome of the patients. Follow-up period was defined
as the interval from the time when patient underwent
first surgery to recurrence of cancer or death (for
uncensored observations) or no recurrence at last
consultation (for censored observations).
Assay methods
Histopathology, tissue microarrays (TMAs) construction and
immunohistochemistry
The histopathologic diagnosis of all cases were re-
examined and confirmed by the oral pathologists at
MSH and AIIMS respectively. The tissue sections com-
prising of more than 70% epithelial cells (cancer/normal)
were selected for further analysis using immunohisto-
chemistry. Tissue microarrays (TMAs) were constructed
using 131 of 235 OSCCs and 99 of 129 normal oral tissues
analyzed in Test set and 74 of 115 OSCCs and 51 normal
oral tissues in Validation set, while the remaining tissues
were used as individual sections for immunostaining as
described below. The construction of TMAs was recently
reported [25]. The TMA blocks were constructed by
relocating small cylindrical tissue cores (two cores per
tissue block representing the cancer sections) from indi-
vidual donor blocks and placing them in a recipient block
with defined array coordinates. Arrays were constructed
from FFPE tissues by the removal of 0.6 mm diametertissue cores from donor blocks. A total of two morpho-
logically representative areas of interest from each
donor block were identified under the microscope by
the pathologists using a stained H&E section as a guide.
Using a precise spacing pattern on manual TMA instru-
ment, 150–200 cores could be transferred to the recipient
paraffin block in a grid like fashion, retaining a link to the
original block and its pathology. Consecutive 4 μm
sections were cut from the recipient block and used for
immunohistochemical staining for S100A2 protein.
Paraffin-embedded TMA sections or individual tissue
sections (4 μm) of human oral non-malignant tissues
and OSCCs collected on gelatin-coated slides were used
for immunostaining as described [25]. In brief, the sec-
tions were deparaffinized in xylene, hydrated in gradient
alcohol followed by antigen retrieval. The sections were
incubated with hydrogen peroxide (0.3% v/v) to quench
the endogenous peroxidase activity, followed by blocking
with 1% bovine serum albumin (BSA) to preclude non-
specific binding. Thereafter, the slides were incubated with
rabbit monoclonal anti-S100A2 antibody (0.5 μg/ml,
[EPR5392] (ab109494, Abcam, CA) for 16 h at 4°C. The
primary antibody was detected using the Dako Envision
kit (Dako CYTOMATION, Glostrup, Denmark) and
diaminobenzidine as the chromogen [6]. Slides were
washed with Tris-buffered saline (TBS, 0.1 M, pH = 7.4),
3–5 times after every step. Finally, the sections were
counterstained with Mayer’s hematoxylin and mounted
with D.P.X mountant. In the negative control tissue sec-
tions, isotype specific non-immune rabbit IgG replaced
the primary antibody. Cervical cancer tissue sections
were used as a positive control for S100A2 expression.
The sections were evaluated by light microscopic examin-
ation using Olympus BX51 microscope (Olympus, NY).
Two researchers from AIIMS (MK, JK) were trained in
MSH for Tissue microarrays (TMAs) construction, immu-
nohistochemical staining and scoring to ensure use of
identical methodologies.
Evaluation of immunohistochemical staining
Each TMA slide or individual tissue section was evaluated
for S100A2 immunoreactivity using a semi-quantitative
scoring system for both staining intensity and the percent-
age of positive epithelial cells as described [25]. Immuno-
positive staining was evaluated in randomly selected five
areas of the tissue section. For S100A2 protein expression,
sections were scored as positive if epithelial cells showed
immunostaining in the nucleus/cytoplasm when observed
independently by three of us, who were blinded to the
clinical outcome (the slides were coded and the scorers
did not have prior knowledge of the local tumor burden,
lymphonodular spread, and grading of the tissue
samples). The tissue sections were scored based on the
% of immunostained cells as: 0–10% = 0; >10–30% = 1;
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were also scored semi-quantitatively on the basis of
staining intensity as negative = 0; mild = 1; moderate = 2;
intense = 3. Finally, a total score was obtained by adding
the score of percentage positivity and intensity therefore
giving a score range from 0 to 7 [25].
Statistical analyses
Statistical analyses were carried out using R version 3.01
(http://www.r-project.org/). The relationships between
S100A2 expression and patients’ characteristics were
compared using Kruskal-Wallis rank sum tests. Nested
Cox regression LRTs were used to guide variable selec-
tion between subcellular % positivity and intensity of
S100A2 immunostaining. LRTs were used to assess
whether: 1) cytoplasm and nucleus variables added inde-
pendent information upon each other that improve the
model fit; and 2) intensity added significant improvement
to model fit upon their respective nuclear or cytoplasmic
% positivity. Thus the most significant subcellular vari-
ables of S100A2 were inferred. Univariate and multivar-
iable Cox regression analyses were used to assess the
prognostic value of S100A2 alone and independent of
clinical and pathological parameters (tumor stage, nodal
status, and histology grade). Two-sided p values were
calculated and p < 0.05 was considered to be significant.
Regression estimates in the Test set (Indian) and Valid-
ation set (Canadian) were compared to assess the stability
of S100A2 as a prognostic factor for cancer recurrence/
death. All model performances were compared using
Harrell’s c-statistic [26]. Internal validations based on
9999 bootstrap samples were used to address potential
overfitting issues, and to correct for optimism. Cox pro-
portional hazards assumption was assessed graphically
and tested using the chi-squared test for goodness of fit
on Schoenfeld residuals [27]. Cox proportional hazard
models were fitted using rms package in R [28]. S100A2
median value derived from the Test sample set was used
to classify subjects into high and low risk groups for
recurrence. Kaplan-Meier plots were used to compare
the survival curves of the high and low risk groups.
Time-dependent Area Under the Curve (AUC) plots
were used to assess improvements of S100A2 upon
common clinical parameters. This was done by compar-
ing the time-dependent AUC of a baseline model using
clinical parameters alone, and an extended baseline
model with both clinical parameters and S100A2. The
clinical relevance of S100A2 to stratify patients into
high and low risk groups for cancer recurrence/death
was assessed using sensitivity, specificity, Positive Pre-
dictive Value (PPV), and Negative Predictive Value
(NPV), and the AUC of the Receiver Operating Charac-
teristics (ROC) curve. The same cut-off value was further
validated in the Validation set.Results
Immunohistochemical analysis of S100A2 expression in
OSCC
To determine the clinical significance of S100A2
protein in oral cancer, its expression was analyzed in
OSCC and histologically normal tissues using a specific
monoclonal antibody by immunohistochemistry. Nuclear
and cytoplasmic staining was scored based on the
percentage of immunopositive cells and intensity of
staining. The results of % positivity of the respective
sub-cellular localization (nuclear and cytoplasmic) are
summarized in Table 1. Figure 2a, b show representative
photomicrographs of S100A2 immunostaining in nor-
mal oral tissue and OSCC respectively. Cervical cancer
used as a positive control showed nuclear and cytoplas-
mic expression of S100A2 protein (Figure 2c), while no
immunostaining was observed in tissue sections used as
negative controls where the primary antibody was
replaced by isotype specific IgG (Figure 2d). Significant
increase in cytoplasmic S100A2 expression was ob-
served in OSCC as compared to the normal oral tissues
p < 0.0001, Test set and p = 0.05, Validation set,
Table 1). In comparison, significant loss of nuclear
S100A2 expression was observed in OSCC as com-
pared to the normal oral tissues p = 0.02, Test set and
p = 0.04, Validation set, Table 1). Importantly, cytoplas-
mic S100A2 showed significant correlation with disease
recurrence (p < 0.01, Test set and p = 0.05, Validation set,
Table 1).Prognostic analyses of S100A2 in oral cancer
Nested Likelihood Ratio Tests (LRTs) of Cox regression
models using the Test set indicated that cytoplasmic %
positivity of S100A2 was the most predictive attribute
for time of recurrence/death (Table 2). Cytoplasmic
S100A2 % positivity was found to be associated with
poor disease prognosis in univariate analysis [Hazard
Ratio HR = 1.35 (95% CI = 1.09, 1.67), p < 0.01, Table 3].
These results were internally validated based on 9999
bootstrap samples (Table 3). External validation was
carried out using an independent cohort of Canadian
patients (validation set). The validation data set showed
similar effect sizes and association levels of S100A2 with
disease prognosis [HR = 1.40 (95% CI = 1.04, 1.90), p =
0.03, Table 3] confirming the applicability of cytoplasmic
S100A2 % positivity as a prognostic factor for cancer
recurrence/death. Multivariable Cox regression analyses
confirmed the prognostic value of S100A2 independent
of clinicopathological parameters [HR = 1.33 (95% CI =
1.07, 1.65), p = 0.01, Table 3]. Internal and external vali-
dations of these findings gave similar results (Table 3).
Loss of nuclear S100A2 expression did not correlate
significantly with disease prognosis.
Table 1 Analysis of S100A2 protein expression and correlation with clinicopathological parameters
Clinicopathological Test set External validation set
Features N Cytoplasmic Nuclear p N Cytoplasmic Nuclear p
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Normal 129 1.29 (0.99) 1.07 (1.29) 51 2.55 (0.88) 2.64 (1.05)
OSCC 235 3.04 (1.26) 0.75 (1.03) <0.00011 115 2.72 (1.06) 2.18 (1.13) 0.051
0.022 0.042
Age (Median, 49 years)
<49 115 2.97 (1.31) 0.75 (1.02) 0.401 17 3.12 (1.17) 2.50 (1.17) 0.051
≥49 120 3.12 (1.20) 0.75 (1.05) 0.862 98 2.70 (1.01) 2.17 (1.12) 0.222
Gender
Male 184 3.05 (1.26) 0.73 (1.01) 0.651 68 2.74 (1.03) 2.24 (1.10) 0.681
Female 51 3.00 (1.26) 0.80 (1.11) 0.902 47 2.81 (1.06) 2.18 (1.17) 0.732
Differentiation
WDSCC 115 3.08 (1.27) 0.81 (1.08) 28 2.82 (1.06) 2.54 (1.10)
MDSCC 113 2.97 (1.27) 0.70 (0.99) 0.461 70 2.86 (0.92) 2.22 (1.08) 0.281
PDSCC 7 3.57 (0.53) 0.57 (0.98) 0.732 17 2.29 (1.36) 1.68 (1.24) 0.062
Clinical stage
I 3 2.67 (2.31) 0.67 (1.15) 30 2.70 (1.29) 2.32 (1.26)
II 38 2.79 (1.26) 0.79 (1.17) 21 2.81 (0.75) 2.48 (1.12)
III 69 3.12 (1.18) 0.65 (0.87) 0.361 21 2.52 (1.03) 1.67 (0.91) 0.601
IV 125 3.09 (1.28) 0.79 (1.08) 0.942 43 2.91 (0.97) 2.29 (1.07) 0.092
Tumor stage
I 6 2.67 (1.51) 1.17 (1.33) 48 2.77 (1.17) 2.25 (1.18)
II 69 2.84 (1.26) 0.81 (1.07) 38 2.53 (0.95) 2.04 (1.22)
III 65 3.20 (1.19) 0.65 (0.89) 0.141 18 3.06 (0.80) 2.28 (0.89) 0.081
IV 95 3.11 (1.28) 0.75 (1.08) 0.712 10 3.30 (0.67) 2.75 (0.72) 0.372
Nodal status
N0 81 2.86 (1.43) 0.68 (0.99) 0.32
1 63 2.78 (1.04) 2.35 (1.11) 0.881
N1–4 154 3.14 (1.15) 0.79 (1.06) 0.46
2 52 2.75 (1.05) 2.06 (1.13) 0.212
Recurrence status3
Non-recurrent 82 2.60 (1.39) 0.80 (1.04) <0.011 47 2.60 (0.92) 2.23 (1.14) 0.051
Recurrent 80 3.30 (1.07) 0.89 (1.13) 0.802 55 2.91 (1.11) 2.16 (1.10) 0.792
1p of Kruskal-Wallis rank sum test on cytoplasmic S100A2 % positivity score; 2p of Kruskal-Wallis rank sum test on nuclear S100A2 % positivity score; 3Only for
OSCC cases with follow up information.
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clinical parameters
The time-dependent AUC plots for the baseline models
(clinical parameters alone), univariate models (cytoplas-
mic S100A2 % positivity) and the extended baseline
models (clinical parameters + cytoplasmic S100A2 %
positivity) in both sample sets confirmed that S100A2
together with clinical parameters hold better discrimin-
atory ability throughout time compared to the use of
clinical parameters alone (Figure 3a, Figure 3b). These
results confirm the independent contribution of S100A2
and in combination with clinical parameters in assessing
disease prognosis.Clinical Utility of S100A2
The median cytoplasmic S100A2 % positivity in OSCCs in
Test set was used to classify patients into high (% positivity
score >3) and low (% positivity score ≤ 3) risk groups.
Kaplan Meier analysis of patients stratified to high and low
risk groups showed significantly different survival probabil-
ities (log rank test, p < 0.00001, Figure 3c). The median sur-
vival time of the higher risk group was found to be
16 months (95% CI = 8.00, 40). This is compared to a
median time survival of 69 months with a 95% CI lower
bound of 14 months. The same cut-off value was used to
stratify patients in the validation set into high and low risk
groups. Kaplan Meier analysis of patients stratified to the
Figure 2 Immunohistochemical analysis of S100A2 in oral tissues. Paraffin-embedded sections of histologically normal mucosa and OSCC
were stained using a rabbit monoclonal anti-S100A2 antibody (0.5 μg/ml, [EPR5392] (ab109494, Abcam, CA) as described in Material & Methods
section. Panel represents (a) normal oral mucosa showing nuclear S100A2 immunostaining; (b) OSCC section illustrating cytoplasmic S100A2 and
loss of nuclear staining in tumor cells; (c) Cervical cancer tissue section showing cytoplasmic S100A2 immunostaining; (d) OSCC section used as a
negative control, showing no S100A2 immunostaining in tumor cells; (original magnification x 200).
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significantly different survival probabilities (log rank test,
p = 0.005, Figure 3d). The median survival time of the high
and low risk groups were found to be 9.4 months (95%
CI = 7.00, 38.1), and 59.9 months (95% CI = 21, −–)
respectively. The consistency of findings in the test set
and validation set confirmed that disease prognosis was
significantly different between the high and low riskTable 2 Variable selection using nested LRT in Test set
Fitted Cox models p*
Nuclear vs. Cytoplasmic S100A2 attributes
Nuclear variables 0.70
Cytoplasmic variables <0.01
Combined nuclear and cytoplasmic variables 0.04
Nested LRT 0.34
Most predictive subcellular variables Cytoplasmic S100A2
% Positivity alone vs. % Positivity & Intensity
Cytoplasmic variables <0.01
Without cytoplasmic intensity <0.01
Nested LRT 0.07
Most predictive variable cytoplasmic % positivity
*p corresponds to the LRT of the model fit, unless stated otherwise.groups. The clinical utility of cytoplasmic S100A2 %
positive score in predicting recurrence/death within
1 year was assessed in both sample sets. Using a cut-off
value of 3, 86% and 81% of patients who had recurrence
/ death within 1 year were correctly stratified into the
high risk group in the Test and Validation sample sets
respectively. Furthermore, 70%, and 81% of subjects
stratified into the low risk groups in both samples did
not show cancer recurrence within 1 year in the Test
and Validation sample sets respectively. The strength of
S100A2 as a tool in clinical settings is mainly due to its
ability to capture the recurrence cases correctly in both
test and validation sets. Consequently, higher percent-
ages of true negatives were stratified to the low risk
group enhancing the negative predictive value of this
stratification approach.
Discussion
A major challenge is to predict the prognosis of OSCC
patients effectively after completion of their primary treat-
ment. In this context our study assumes importance,
because of its retrospective nature, the large set of patients
representing different stages of OSCC from two independ-
ent cohorts and long-term follow-up analysis. Our study
uniquely based on sub-cellular compartment analysis of
Table 3 Cox regression analyses
Predictors Test set (n = 162) Internal validation of test set* External validation set (n = 102)
HR [95% CI] p c-statistic HR [95% CI] p c-statistic HR [95% CI] p c-statistic
Univariate analyses
Cyto S100A2 % Pos 1.35 [1.09, 1.67] <0.01 0.59 1.35 [1.10, 1.76] 0.01 0.59€ 1.40 [1.04, 1.90] 0.03 0.60
Multivariable analyses adjusted for clinical parameters
Cyto S100A2 % Pos 1.33 [1.07, 1.65] 0.01 0.62 1.34 [1.08, 1.78] 0.03 0.59€ 1.47 [1.07, 2.03] 0.02 0.67
Histology grade 1.32 [0.91, 1.91] 0.14 1.32 [0.90, 1.92] 0.14 1.03 [0.65, 1.64] 0.90
Clinical stage 1.06 [0.60, 1.89] 0.83 1.07 [0.59, 1.93] 0.84 1.00 [0.65, 1.54] 0.99
Nodal status 1.30 [0.68, 2.51] 0.43 1.33 [0.69, 2.82] 0.45 2.09 [0.89, 4.92] 0.09
Tumor stage 1.10 [0.72, 1.70] 0.65 1.11 [0.71, 1.77] 0.67 1.23 [0.86, 1.78] 0.25
*Internal validations were based on 9999 bootstrap samples; €Optimism corrected c-statistic.
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gave a more comprehensive insight into the clinical rele-
vance of alterations in sub-cellular localization of a protein
on disease outcome. Interestingly, a subset of patients
having OSCC showed increased cytoplasmic S100A2
expression and loss of nuclear S100A2 expression in these
tissues as compared to normal tissues. Furthermore, the
cytoplasmic overexpression of this protein in OSCCs was
associated with disease recurrence. Hence, our study
emphasizes the importance of sub-cellular compartmental
analysis of S100A2 protein in cytoplasm and nucleus as
compared to the overall protein expression reported in
most earlier studies [19,29].
Our findings are supported by a recent study that
demonstrated S100A2 is required for TGF-β induced
cell migration and cell invasion [20]. These authors pro-
posed that interaction of S100A2 with smads in the
cytoplasm leading to protein stabilization is a necessary
step for TGF-β induced tumorigenesis [20]. Bulk et al.,
(2009) reported S100A2 overexpression induced migra-
tion, invasion and metastasis in lung cancer suggesting a
central role for this protein in proliferation pathways,
and its potential to serve as a therapeutic target for
treatment of inflammation and cancer. Tissue micro-
scopic examination has shown higher expression of
S100A2 predominantly in the proliferative layer
suggesting S100A2 may be a molecular player during the
inflammatory cell response and disease progression, a
role supported by the finding that overexpression of
S100A2 attracts inflammatory eosinophils during im-
mune response [21]. Importantly, recent demonstration
of the pro-tumorigenic actions of S100A2 in lung cancer
cells involving regulation of PI3K/Akt signaling and
functional interaction with Smad3, which is enhanced
in the presence of calcium and TGF-β and induces
epithelial-mesenchymal transition (EMT) [20], further
support our clinical findings of increased cytoplasmic
and decreased nuclear S100A2 expression in OSCC.
Loss of nuclear S100A2 has been reported in multiplecancers including early stage oral cancer, pancreatic
cancer, non-small cell lung carcinoma [18] and our find-
ings of nuclear loss of S100A2 support these studies.
However, most studies did not investigate the clinical
significance of cytoplasmic S100A2. Changes in sub-
cellular localization of proteins often affect their normal
cellular function. Using oral cancer cell lines, Mueller
et al., showed that S100A2 protein translocated from the
cytoplasm to the nucleus and co-localized with tumor
suppressor p53 and increased its transcriptional activity
thereby modulating cellular proliferation [8]. Our study
underscores the biological relevance of nuclear loss of
S100A2 expression and its cytoplasmic accumulation in
oral cancer. Notably, cytoplasmic S100A2 expression
emerged as a poor prognosticator in OSCC underscoring
the clinical significance of S100A2 in oral cancer. The
time-dependent AUC plots showed that S100A2 alone
had comparable discriminatory ability to the clinical
parameters throughout survival time. The unique aspect
of our study is the validation of prognostic utility of
S100A2 in an independent external cohort (Canadian)
which showed similar association with disease outcome
as observed in the test set comprising of Indian patients.
The robustness of our findings was supported by internal
validation of prognostic utility of S100A2 in the Test set
by bootstrapping. Based on cytoplasmic S100A2 expres-
sion levels, the stratification of OSCC patients into high
and low risk groups accurately predicted their disease out-
come; 86% and 81% of patients who had recurrence/death
within 1 year were correctly stratified into the high risk
group in the Test and Validation sets respectively.
Furthermore, 70% and 81% of subjects stratified into
the low risk groups in both sets did not show cancer
recurrence within 1 year respectively. The strength of
S100A2 as a tool in clinical settings is mainly due to its
ability to capture the recurrence cases accurately. Con-
sequently, higher percentages of true negatives were
stratified to the low risk group enhancing the negative
predictive value of this stratification approach. One
Figure 3 Time-dependent AUC plots of cytoplasmic S100A2 in OSCC and evaluation of S100A2 overexpression as a prognostic marker
of OSCC. Time-dependent AUC plots for a baseline model (clinical parameters alone), a univariate model (cytoplasmic S100A2 % positivity) and
an extended baseline model (clinical parameters + cytoplasmic S100A2 % positivity) in a. Test set and b. Validation set. c. Survival curves of the high
risk and low risk groups in the Test set. Median survival times (months): High risk group - 16 (95% CI = 8.00, 40); Low risk group - 69 (95% CI = 14, −–).
b. Survival curves of the high risk and low risk groups in the validation set. Median survival times (months): High risk group - 9.4 (95% CI = 7.00, 38.1);
Low risk group - 59.9 (95% CI = 21, −–).
Kumar et al. Journal of Translational Medicine  (2015) 13:8 Page 9 of 10limitation of our study is that it does not provide mech-
anistic insight into the role of S100A2 in oral cancer. In
conclusion, we demonstrate S100A2 is overexpressed in
oral cancer. Importantly, cytoplasmic S100A2 emerged
as an independent predictor of recurrence in OSCC
patients suggesting its potential to serve as a prognostic
marker in oral cancer patients.Competing interests
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